Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: A case report

J Eur Acad Dermatol Venereol. 2024 May;38(5):e434-e436. doi: 10.1111/jdv.19667. Epub 2023 Dec 7.

Authors

B Kurz¹, I Ivanova¹, K Drexler¹, M Berneburg¹, F Günther², D Niebel¹

Affiliations

¹ Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
² Department of Rheumatology, Asklepios Klinikum, Bad Abbach, Germany.

PMID: 38059369
DOI: 10.1111/jdv.19667

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Administration, Oral
Female
Humans
Lupus Erythematosus, Cutaneous* / drug therapy
Middle Aged
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors